



```

                                     EcoRI
                                     BstBI
End of mCherry                    XhoI
3506 CTG TAC AAG TCC GGA CTC AGA TCT CGA GCT CAA GCT TCG AAT TCT
                                     ApaI   BamHI
                                     SmaI/XmaI
3551 GCA GTC GAC GGT ACC GCG GGC CCG GGA TCC ACC GGA TCT AGA TAA
                                     Stop   Stop
                                     Stop
3596 CTG ATC

```

#### pLVX-mCherry-C1 Vector Map and Multiple Cloning Site (MCS).

#### Description

pLVX-mCherry-C1 is an HIV-1-based, lentiviral expression vector that allows you to express your gene of interest fused to mCherry, a mutant fluorescent protein derived from the tetrameric *Discosoma sp.* red fluorescent protein, DsRed (1). The excitation and emission maxima of the native mCherry protein are 587 nm and 610 nm, respectively. Genes cloned into the multiple cloning site (MCS), located at the C-terminal end of the mCherry coding sequence, are expressed as C-terminal mCherry fusion proteins. Expression of the fusion protein is driven by the constitutively active human cytomegalovirus immediate early promoter ( $P_{CMV IE}$ ), located just upstream of the mCherry coding sequence. Lentiviral particles derived from the vector allow the expression of mCherry fusion proteins in virtually any cell type, including primary cells. The unmodified vector expresses mCherry, and may be used to produce marker virus to optimize infection protocols.

pLVX-mCherry-C1 contains all of the viral processing elements necessary for the production of replication-incompetent lentivirus, as well as elements to improve viral titer, transgene expression, and overall vector function. The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) promotes RNA processing events and enhances nuclear export of viral and transgene RNA (2), leading to increased viral titers from packaging cells, and enhanced expression of your gene of interest in target cells. In addition, the vector includes a Rev-response element (RRE), which further increases viral titers by enhancing the transport of unspliced viral RNA out of the nucleus (3). Finally, pLVX-mCherry-C1 also contains a central polypurine tract/central termination sequence element (cPPT/CTS). During target cell infection, this element creates a central DNA flap that increases nuclear import of the viral genome, resulting in improved vector integration and more efficient transduction (4).

(PR9X3368; published 30 October 2009)



**Clontech**

United States/Canada  
800.662.2566

Asia Pacific  
+1.650.919.7300

Europe  
+33.(0)1.3904.6880

Japan  
+81.(0)77.543.6116

Clontech Laboratories, Inc.  
A Takara Bio Company  
1290 Terra Bella Ave.  
Mountain View, CA 94043  
Technical Support (US)  
E-mail: tech@clontech.com  
www.clontech.com

In addition to lentiviral elements, pLVX-mCherry-C1 contains a puromycin resistance gene (Puro<sup>r</sup>) under the control of the murine phosphoglycerate kinase (PGK) promoter ( $P_{PGK}$ ) for the selection of stable transductants. The vector also contains a pUC origin of replication and an *E. coli* ampicillin resistance gene (Amp<sup>r</sup>) for propagation and selection in bacteria.

### Use

To construct a fusion protein, the gene of interest must be cloned into pLVX-mCherry-C1 so that it is in-frame with the mCherry coding sequence. The inserted sequence does not require an initiation codon (ATG) or a stop codon (TAA, TAG, TGA); however, if you don't want to use the stop codons downstream of the MCS (see map), you can add a stop codon to the end of your gene of interest.

The fusion protein is constitutively expressed when pLVX-mCherry-C1 is transduced into target cells. Before the vector can be transduced, however, it must be transfected into 293T packaging cells with our Lenti-X™ HT Packaging System (Cat. Nos. 632160 and 632161). This packaging system allows you to safely produce high titer, infectious, replication-incompetent, VSV-G pseudotyped lentiviral particles that can infect a wide range of cell types, including non-dividing and primary cells (5).

### Location of Features

- 5' LTR: 1–635
- PBS (primer binding site): 636–653
- Ψ (packaging signal): 685–822
- RRE (Rev-response element): 1303–1536
- cPPT/CTS (central polypurine tract/central termination sequence): 2028–2151
- $P_{CMVIE}$  (human cytomegalovirus immediate early promoter): 2185–2787
- mCherry fluorescent protein gene: 2807–3514
- MCS (multiple cloning site): 3528–3580
- $P_{PGK}$  (phosphoglycerate kinase promoter): 3604–4112
- Puro<sup>r</sup> (puromycin resistance gene): 4133–4732
- WPRE (woodchuck posttranscriptional regulatory element): 4746–5337
- 3' LTR: 5540–6176
- pUC origin of replication: 6646–7319 (complementary)
- Amp<sup>r</sup> (ampicillin resistance gene; β-lactamase): 7464–8460 (complementary)

### Selection of Stable Transfectants

- Selectable marker: plasmid confers resistance to puromycin.

### Propagation in *E. coli*

- Suitable host strains: DH5α™, DH10B and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 µg/ml) in *E. coli* hosts.
- *E. coli* replication origin: ColE1
- Copy number: high

### Excitation and emission maxima of mCherry

- Excitation maximum = 587 nm
- Emission maximum = 610 nm

### Notes:

The vector sequence was compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

The viral supernatants produced by this lentiviral vector could contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant lentivirus. Appropriate NIH, regional, and institutional guidelines apply.

## References

1. Shaner, N.C. *et al.* (2004) *Nat. Biotechnol.* **22**(12):1567–1572.
2. Zufferey, R. *et al.* (1999) *J. Virol.* **73**(4):2886–2892.
3. Cochrane, A. W. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**(3):1198–1202.
4. Zennou, V. *et al.* (2000) *Cell* **101**(2):173–185.
5. Wu, X. *et al.* (2000) *Mol. Ther.* **2**(1):47–55.

## Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

DH5 $\alpha$ <sup>™</sup> is a trademark of Invitrogen Corporation.

### cPPT/CTS Element:

This product and its use are the subject of U.S. Pat. No. 6,682,907. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Clontech is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 ([www.pasteur.fr](http://www.pasteur.fr)).

### DsRed-Monomer and Fruit Fluorescent Proteins:

The DsRed-Monomer and the Fruit Fluorescent Proteins are covered by one or more of the following U.S. patents: 7,005,511; 7,157,566; 7,393,923 and 7,250,298.

### Living Colors<sup>®</sup> Fluorescent Protein Products:

Not-For-Profit Entities: Orders may be placed in the normal manner by contacting your local representative or Clontech Customer Service at 650.919.7300. At its discretion, Clontech grants Not-For-Profit Entities a non-exclusive, personal, limited license to use this product for non-commercial life science research use only. Such license specifically excludes the right to sell or otherwise transfer this product, its components or derivatives thereof to third parties. No modifications to the protein coding sequence may be made without express written permission from Clontech. Any other use of this product requires a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com).

For-Profit Entities wishing to use this product are required to obtain a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com) or click here for more information.

### WPRES Purchaser Notification:

Clontech has a license to sell products containing WPRES, under the terms described below. Any use of WPRES outside of Clontech's product or the product's intended use, requires a license as detailed below. Before using the product containing WPRES, please read the following license agreement. If you do not agree to be bound by its terms, contact Clontech within 10 days for authorization to return the unused product containing WPRES and to receive a full credit.

Patents: The WPRES technology is covered by one or more of the following US patents and corresponding patent claims outside the US: 6,136,597 ; 6,284,469 ; 6,312,912 ; 6,287,814 , issued to The Salk Institute for Biological Studies

Individual License Agreement: Clontech grants you a non-exclusive license to use the enclosed product containing WPRES in its entirety for its intended use. The product is being transferred to you in furtherance of, and reliance on, such license. Any use of WPRES outside of Clontech's product or the product's intended use, requires a license from the Salk Institute for Biological Studies.

Termination of License: This license agreement is effective until terminated. You may terminate it at any time by destroying all products containing WPRES in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all products containing WPRES in your control, and so notify Clontech in writing. This License shall be governed in its interpretation and enforcement by the laws of the State of California.

### Contact for WPRES Licensing:

The Salk Institute for Biological Studies  
10010 North Torrey Pines Road  
La Jolla, CA 92037  
Attn.: Office of Technology Management  
Phone: 858.453.4100 ext. 1275  
Fax: 858.546.8093

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2009 Clontech Laboratories, Inc